Yosemite-backed Azalea reaches Phase 2 clinical trials by 2027-06-30
Resolves: Azalea announces the initiation of Phase 2 clinical trials in at least one oncology indication by June 30, 2027.
user-generated· product
Yosemite-backed Azalea reaches Phase 2 clinical trials by 2027-06-30
Market overview
Azalea, one of Yosemite's portfolio companies born from a grant to Jennifer Doudna's lab, is focused on oncology. Given the firm's emphasis on accelerating drug development with AI and the current momentum in its pipeline, Azalea is likely to progress to Phase 2 trials within 12-18 months.
product prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
Azalea announces the initiation of Phase 2 clinical trials in at least one oncology indication by June 30, 2027.
Source: user-generated
More product markets
- Will Ocado partnership meet 35% productivity target? — 70% Yes
- Will DCI announce new EV contract worth >$50M? — 55% Yes
- Will the company announce a renewable energy contract by 2026-12-31? — 65% Yes
- Will enGene Therapeutics report positive interim data for DETAIL trial by Q1 2027? — 35% Yes
- Will Phase 2 enrollment reach 50/60 patients by 2026-12-31? — 90% Yes
- Will ServiceTitan announce a major AI partnership or acquisition by end of 2026? — 30% Yes
- Will fintech firms offering real-time fund verification see increased demand? — 75% Yes
- Will private label exceed 33% penetration by EOY? — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…